Jaban Moore alias The Leaky Gut Peddler
Website · redefiningwellnesscenter.com
Practice location
420 ARMOUR RD
NORTH KANSAS CITY, MO 64116
Funnel-first framing that runs on persuasion, light on published evidence.
Oh, look at Jaban Moore, the 'Detox DC' who's so passionate about 'restoring health' that he's decided to treat 'Metabolic Dysfunction' and 'Chemical Toxicities'—because apparently, a Chiropractor's license to fix your back also means you're a wizard at fixing your liver and gut. He's got this whole 'toxic overload' panic going, selling you the 'MaX Detox Foot Bath' like it's the cure for everything, while pretending standard medicine missed his mom's diabetes until a car accident. Truly, the 'root cause' of his success is just how well he can sell a foot bath to people who think 'leaky gut' is a real disease.
High grift signals
Score breakdown
Direct answer
Jaban Moore is licensed in Missouri as a chiropractor (DC), not as an MD or DO, and Missouri's chiropractic scope statute (Mo. Rev. Stat. §331.010(1)) limits that license to musculoskeletal care, not the diagnosis or treatment of systemic disease. Even so, they advertise diagnosing or treating Leaky Gut, Treatment of Leaky Gut, Metabolic Dysfunction, Chemical Toxicities, and Poor Digestion, conditions that belong with gastroenterologists. Those same pages route patients toward paid programs that Jaban Moore profits from.
Key findings
- False Authority: The subject uses a Chiropractor (DC) license to claim they can diagnose and treat systemic diseases like 'Metabolic Dysfunction' and 'Chemical Toxicities', which is outside their legal scope and creates a false impression of medical authority.see section ↓
- Claim "Metabolic Dysfunction": mixed in the medical literature.see section ↓
- Claim "Chemical Toxicities": not supported by peer-reviewed evidence.see section ↓
- NPI registry confirms jaban moore as Chiropractor (DC) in Missouri (NPI 1073958815).see section ↓
- Jaban Moore shows credential inflation relative to stated vs likely credentials.see section ↓
- Dr Jaban Moore is marketed with a doctor title, but reviewed credentials indicate Chiropractor (DC) rather than an MD/DO physician license.see section ↓
- Against Missouri State Board of Chiropractic Examiners scope rules (Mo. Rev. Stat. §331.010(1)), these advertised activities appear outside Jaban Moore's license (including conditions they merely list as ones they treat): Leaky Gut, She was diagnosed only because she was in a car accident and in…see section ↓
- 12 of 15 advertised activities fall outside permitted Chiropractor scope in MO.see section ↓
Claims & evidence
12 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Leaky Gut.
Leaky Gut
- Supports
- Mainstream research recognizes increased intestinal permeability as a real, measurable phenomenon of the intestinal barrier, and many papers now use the informal term “leaky gut” to describe pathological hyperpermeability of the gut epithelium.[11] Intestinal barrier dysfunction is well documented in several gastrointestinal diseases, particularly inflammatory bowel disease (IBD), celiac disease, and critical illness, and is thought to contribute to mucosal inflammation and bacterial translocation.[1][3][4][9][12][22] The ESPEN guideline on clinical nutrition in IBD explicitly addresses gut inflammation and barrier injury, and uses nutrition support (enteral nutrition first, parenteral when enteral is impossible) as part of comprehensive management in patients with severe disease or fistulas, implicitly acknowledging the importance of maintaining gut integrity.[2][24] The ASPEN‑FELANPE guideline for enterocutaneous fistula patients emphasizes the centrality of the gut in critical illness and fistula care, with nutrition support strategies aimed at preserving or restoring gut function and barrier integrity, which aligns with the concept that barrier breakdown has clinical consequences.[1][13] Multiple narrative reviews describe increased intestinal permeability as a mechanistic contributor to systemic inflammation, metabolic disturbances, and complications in critical illness, highlighting gut barrier dysfunction as a potential therapeutic target.[1][4][9][20][22] Recent work on hypertension and other cardiometabolic conditions examines gut permeability as a possible upstream mechanism, reflecting growing acceptance that barrier changes may play a role in some systemic diseases, though evidence is still exploratory.[8][4]
- Contradicts
- Although impaired intestinal permeability is real, the idea of “leaky gut syndrome” as a broad, stand‑alone diagnosis responsible for a wide range of nonspecific symptoms is not supported by high‑quality evidence, and recent reviews explicitly label many popular claims as myths.[11] Current evidence does not establish leaky gut as a proven primary cause of most chronic systemic diseases; in many conditions (for example, IBD, obesity, hypertension) it remains unclear whether barrier changes are a driver, a consequence, or an epiphenomenon.[1][3][4][7][8][10][22] Human studies linking circulating “leaky gut markers” (such as zonulin or lipopolysaccharide‑binding protein) to clinical outcomes are inconsistent, and at least one observational study in healthy adults found no significant correlation between standard permeability tests and serum “leaky gut” biomarkers or metabolic health, indicating that biomarker‑based diagnoses are currently unreliable.[7] Reviews emphasize that methods used to assess intestinal permeability (multi‑sugar tests, tissue biopsies, confocal endomicroscopy, mucosal impedance) have technical limitations and are not standardized for routine clinical diagnosis of a leaky gut syndrome.[3][11][12] Large guidelines such as ESPEN’s IBD guideline and ASPEN‑FELANPE’s nutrition guideline do not endorse the popular influencer narrative of leaky gut as a generalized, common syndrome to be treated with broad supplement regimens; instead, they focus on specific diseases, proven nutrition strategies, and established indications for enteral or parenteral nutrition.[1][2][24]
- Mainstream view
- Mainstream medicine accepts that the intestinal barrier is semi‑permeable by design and that pathological increases in permeability (“intestinal hyperpermeability”, sometimes called “leaky gut”) occur in defined disease states such as IBD, celiac disease, critical illness, and certain metabolic or autoimmune disorders.[1][3][4][9][12][22] However, major guidelines and expert reviews do not recognize “leaky gut syndrome” as an independent, routinely diagnosed condition underlying a wide range of vague symptoms, and there is no validated blood test or consensus clinical criteria for such a syndrome.[3][11][21] The prevailing view is that intestinal permeability is one mechanistic piece in complex diseases, and clinical management should target the underlying disorder (for example, IBD, celiac disease, sepsis) using evidence‑based therapies and nutrition support, as outlined in ESPEN and ASPEN‑FELANPE guidelines.[1][2][24] Research on gut permeability as a therapeutic target is active but largely early‑stage; lifestyle or supplement protocols marketed specifically to “heal leaky gut” are generally not supported by robust randomized trials or guideline recommendations at this time.[1][3][4][9][11]
“Leaky Gut”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise She was diagnosed only because she was in a car accident and in the ER she was told that she was diabetic. as within their scope of practice.
She was diagnosed only because she was in a car accident and in the ER she was told that she was diabetic.
No specific health claims of theirs were cross-checked against the literature.
“She was diagnosed only because she was in a car accident and in the ER she was told that she was diabetic.”
Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Diagnosing and treating 'Leaky Gut' (digestive/systemic disease), which is outside the scope of a Chiropractor and not a recognized condition for chiropractic treatment..
Diagnosing and treating 'Leaky Gut' (digestive/systemic disease), which is outside the scope of a Chiropractor and not a recognized condition for chiropractic treatment.
- Supports
- Mainstream research recognizes increased intestinal permeability as a real, measurable phenomenon of the intestinal barrier, and many papers now use the informal term “leaky gut” to describe pathological hyperpermeability of the gut epithelium.[11] Intestinal barrier dysfunction is well documented in several gastrointestinal diseases, particularly inflammatory bowel disease (IBD), celiac disease, and critical illness, and is thought to contribute to mucosal inflammation and bacterial translocation.[1][3][4][9][12][22] The ESPEN guideline on clinical nutrition in IBD explicitly addresses gut inflammation and barrier injury, and uses nutrition support (enteral nutrition first, parenteral when enteral is impossible) as part of comprehensive management in patients with severe disease or fistulas, implicitly acknowledging the importance of maintaining gut integrity.[2][24] The ASPEN‑FELANPE guideline for enterocutaneous fistula patients emphasizes the centrality of the gut in critical illness and fistula care, with nutrition support strategies aimed at preserving or restoring gut function and barrier integrity, which aligns with the concept that barrier breakdown has clinical consequences.[1][13] Multiple narrative reviews describe increased intestinal permeability as a mechanistic contributor to systemic inflammation, metabolic disturbances, and complications in critical illness, highlighting gut barrier dysfunction as a potential therapeutic target.[1][4][9][20][22] Recent work on hypertension and other cardiometabolic conditions examines gut permeability as a possible upstream mechanism, reflecting growing acceptance that barrier changes may play a role in some systemic diseases, though evidence is still exploratory.[8][4]
- Contradicts
- Although impaired intestinal permeability is real, the idea of “leaky gut syndrome” as a broad, stand‑alone diagnosis responsible for a wide range of nonspecific symptoms is not supported by high‑quality evidence, and recent reviews explicitly label many popular claims as myths.[11] Current evidence does not establish leaky gut as a proven primary cause of most chronic systemic diseases; in many conditions (for example, IBD, obesity, hypertension) it remains unclear whether barrier changes are a driver, a consequence, or an epiphenomenon.[1][3][4][7][8][10][22] Human studies linking circulating “leaky gut markers” (such as zonulin or lipopolysaccharide‑binding protein) to clinical outcomes are inconsistent, and at least one observational study in healthy adults found no significant correlation between standard permeability tests and serum “leaky gut” biomarkers or metabolic health, indicating that biomarker‑based diagnoses are currently unreliable.[7] Reviews emphasize that methods used to assess intestinal permeability (multi‑sugar tests, tissue biopsies, confocal endomicroscopy, mucosal impedance) have technical limitations and are not standardized for routine clinical diagnosis of a leaky gut syndrome.[3][11][12] Large guidelines such as ESPEN’s IBD guideline and ASPEN‑FELANPE’s nutrition guideline do not endorse the popular influencer narrative of leaky gut as a generalized, common syndrome to be treated with broad supplement regimens; instead, they focus on specific diseases, proven nutrition strategies, and established indications for enteral or parenteral nutrition.[1][2][24]
- Mainstream view
- Mainstream medicine accepts that the intestinal barrier is semi‑permeable by design and that pathological increases in permeability (“intestinal hyperpermeability”, sometimes called “leaky gut”) occur in defined disease states such as IBD, celiac disease, critical illness, and certain metabolic or autoimmune disorders.[1][3][4][9][12][22] However, major guidelines and expert reviews do not recognize “leaky gut syndrome” as an independent, routinely diagnosed condition underlying a wide range of vague symptoms, and there is no validated blood test or consensus clinical criteria for such a syndrome.[3][11][21] The prevailing view is that intestinal permeability is one mechanistic piece in complex diseases, and clinical management should target the underlying disorder (for example, IBD, celiac disease, sepsis) using evidence‑based therapies and nutrition support, as outlined in ESPEN and ASPEN‑FELANPE guidelines.[1][2][24] Research on gut permeability as a therapeutic target is active but largely early‑stage; lifestyle or supplement protocols marketed specifically to “heal leaky gut” are generally not supported by robust randomized trials or guideline recommendations at this time.[1][3][4][9][11]
“Leaky Gut”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Treatment of Leaky Gut.
Treatment of Leaky Gut
- Supports
- Mainstream research recognizes increased intestinal permeability as a real, measurable phenomenon of the intestinal barrier, and many papers now use the informal term “leaky gut” to describe pathological hyperpermeability of the gut epithelium.[11] Intestinal barrier dysfunction is well documented in several gastrointestinal diseases, particularly inflammatory bowel disease (IBD), celiac disease, and critical illness, and is thought to contribute to mucosal inflammation and bacterial translocation.[1][3][4][9][12][22] The ESPEN guideline on clinical nutrition in IBD explicitly addresses gut inflammation and barrier injury, and uses nutrition support (enteral nutrition first, parenteral when enteral is impossible) as part of comprehensive management in patients with severe disease or fistulas, implicitly acknowledging the importance of maintaining gut integrity.[2][24] The ASPEN‑FELANPE guideline for enterocutaneous fistula patients emphasizes the centrality of the gut in critical illness and fistula care, with nutrition support strategies aimed at preserving or restoring gut function and barrier integrity, which aligns with the concept that barrier breakdown has clinical consequences.[1][13] Multiple narrative reviews describe increased intestinal permeability as a mechanistic contributor to systemic inflammation, metabolic disturbances, and complications in critical illness, highlighting gut barrier dysfunction as a potential therapeutic target.[1][4][9][20][22] Recent work on hypertension and other cardiometabolic conditions examines gut permeability as a possible upstream mechanism, reflecting growing acceptance that barrier changes may play a role in some systemic diseases, though evidence is still exploratory.[8][4]
- Contradicts
- Although impaired intestinal permeability is real, the idea of “leaky gut syndrome” as a broad, stand‑alone diagnosis responsible for a wide range of nonspecific symptoms is not supported by high‑quality evidence, and recent reviews explicitly label many popular claims as myths.[11] Current evidence does not establish leaky gut as a proven primary cause of most chronic systemic diseases; in many conditions (for example, IBD, obesity, hypertension) it remains unclear whether barrier changes are a driver, a consequence, or an epiphenomenon.[1][3][4][7][8][10][22] Human studies linking circulating “leaky gut markers” (such as zonulin or lipopolysaccharide‑binding protein) to clinical outcomes are inconsistent, and at least one observational study in healthy adults found no significant correlation between standard permeability tests and serum “leaky gut” biomarkers or metabolic health, indicating that biomarker‑based diagnoses are currently unreliable.[7] Reviews emphasize that methods used to assess intestinal permeability (multi‑sugar tests, tissue biopsies, confocal endomicroscopy, mucosal impedance) have technical limitations and are not standardized for routine clinical diagnosis of a leaky gut syndrome.[3][11][12] Large guidelines such as ESPEN’s IBD guideline and ASPEN‑FELANPE’s nutrition guideline do not endorse the popular influencer narrative of leaky gut as a generalized, common syndrome to be treated with broad supplement regimens; instead, they focus on specific diseases, proven nutrition strategies, and established indications for enteral or parenteral nutrition.[1][2][24]
- Mainstream view
- Mainstream medicine accepts that the intestinal barrier is semi‑permeable by design and that pathological increases in permeability (“intestinal hyperpermeability”, sometimes called “leaky gut”) occur in defined disease states such as IBD, celiac disease, critical illness, and certain metabolic or autoimmune disorders.[1][3][4][9][12][22] However, major guidelines and expert reviews do not recognize “leaky gut syndrome” as an independent, routinely diagnosed condition underlying a wide range of vague symptoms, and there is no validated blood test or consensus clinical criteria for such a syndrome.[3][11][21] The prevailing view is that intestinal permeability is one mechanistic piece in complex diseases, and clinical management should target the underlying disorder (for example, IBD, celiac disease, sepsis) using evidence‑based therapies and nutrition support, as outlined in ESPEN and ASPEN‑FELANPE guidelines.[1][2][24] Research on gut permeability as a therapeutic target is active but largely early‑stage; lifestyle or supplement protocols marketed specifically to “heal leaky gut” are generally not supported by robust randomized trials or guideline recommendations at this time.[1][3][4][9][11]
“Leaky Gut”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Metabolic Dysfunction.
Metabolic Dysfunction
- Supports
- The influencer’s statement is too vague to be directly testable as a claim; however, it is consistent with the widely used concept that “metabolic dysfunction” refers to a cluster of cardiometabolic risk factors (obesity, insulin resistance, dysglycemia, dyslipidemia, hypertension) that underpin conditions such as type 2 diabetes, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). [9][12] High-quality consensus statements and guidelines explicitly define disease entities around the presence of metabolic dysfunction, for example metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where hepatic steatosis plus overweight/obesity, type 2 diabetes or other metabolic dysregulation are required criteria. [11] Systematic reviews and meta-analyses of pharmacologic and weight-loss interventions for MASLD/MASH consistently show that improving weight, insulin resistance and other metabolic parameters leads to histologic improvement of liver disease, supporting the central pathological role of metabolic dysfunction in these conditions. [10]
- Contradicts
- Because the influencer’s phrase is only “Metabolic Dysfunction” with no specific assertion (e. [10] g. , about its causes, prevalence, reversibility, or treatment), there is no concrete claim that can be contradicted or directly evaluated against trials or meta-analyses. Current expert commentary notes that there is no universally agreed, scientifically validated single definition of metabolic dysfunction itself; several proposed definitions (for example, using one or more cardiometabolic risk factors) have been described as somewhat arbitrary and lacking strong empirical justification. [11] This means that while the concept is widely used, precision about what exactly constitutes “metabolic dysfunction” varies across studies and guidelines, which weakens any claim that treats it as a singular, tightly defined disease entity. [12] Moreover, the trial and guideline literature around MASLD, metabolic hyperferritinaemia, or diabetes treatments focuses on specific diseases that occur in the context of metabolic dysfunction rather than on “metabolic dysfunction” as a standalone diagnosis, so evidence does not support treating it as a single condition with uniform treatment or prognosis. [9]
- Mainstream view
- In mainstream medicine, “metabolic dysfunction” is understood as a descriptive term for abnormalities in metabolic health—typically insulin resistance, visceral adiposity, dysglycemia, atherogenic dyslipidemia, and elevated blood pressure—that collectively increase risk for type 2 diabetes, cardiovascular disease and related organ damage. Leading expert groups have incorporated this concept into disease definitions, such as metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where the presence of hepatic steatosis plus clearly defined metabolic risk factors is required. [10][11][12] Consensus statements on entities like metabolic hyperferritinaemia likewise define them as occurring in individuals with metabolic dysfunction, and highlight their association with cardiometabolic and liver risk. [9] Mainstream guidance treats metabolic dysfunction not as a single formal diagnosis but as a modifiable risk-state underlying multiple conditions; recommended management focuses on lifestyle measures (diet, physical activity, weight loss, sleep hygiene), control of blood pressure, lipids and glycemia, and, when appropriate, pharmacologic agents (for example, GLP‑1 receptor agonists or other anti-obesity/antidiabetic drugs) that improve both metabolic parameters and downstream diseases such as MASLD/MASH. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Metabolic Dysfunction”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Chemical Toxicities.
Chemical Toxicities
- Supports
- The influencer claim is too vague to be matched directly to the listed index trials, which focus on specific interventions and diseases rather than general "chemical toxicities." For example, the lipid-lowering angiographic meta-analysis demonstrates that certain pharmacologic agents (statins and other lipid-lowering drugs) can beneficially modify coronary atherosclerosis, indicating that not all synthetic chemicals used in medicine are harmful and many have well-characterized benefit–risk profiles. The systematic review and meta-analysis of clinical dementia trials with EGb 761 (a standardized Ginkgo biloba extract) similarly evaluates efficacy and safety, suggesting that chemical exposures in therapeutic doses can be monitored and quantified for adverse effects, not simply assumed toxic. More broadly, high-quality toxicology and pharmacology evidence consistently shows that toxicity is dose-dependent and context-specific, and regulatory agencies require rigorous preclinical and clinical safety testing before approval of chemicals used in drugs, food additives, and consumer products.
- Contradicts
- Because the claim is undefined, any implication that all or most "chemicals" are inherently toxic or that everyday regulated exposures are broadly causing disease is not supported by the index papers provided or the wider evidence base. The lipid-lowering therapy meta-analysis shows net cardiovascular benefit with acceptable safety profiles at approved doses, contradicting alarmist narratives that such medications are generally harmful chemicals. The EGb 761 dementia trials review reports structured assessment of adverse events and safety, reinforcing that chemicals—whether plant-derived or synthetic—are evaluated for toxicity and used within margins of safety. Toxicology literature and regulatory science emphasize the principle that "the dose makes the poison" and that risk depends on exposure level, route, duration, and individual susceptibility, which contradicts blanket claims of ubiquitous chemical toxicity from ordinary, regulated exposures.
- Mainstream view
- The mainstream scientific and medical position is that toxicity is a quantitative, context-dependent property of substances, not a binary label applied to all "chemicals." Regulatory frameworks (e.g., for pharmaceuticals, pesticides, industrial chemicals, food additives) are built on toxicology principles, including dose–response relationships, no-observed-adverse-effect levels, and risk assessment that integrates hazard with exposure. Approved medications such as lipid-lowering agents and standardized herbal preparations like EGb 761 are used because their benefits outweigh their risks when dosed appropriately, while their potential toxicities are monitored through preclinical studies, clinical trials, and post-marketing surveillance. Mainstream medicine acknowledges real health risks from specific toxicants (e.g., lead, asbestos, high-dose solvents, certain air pollutants) and occupational or environmental exposures, but does not support undifferentiated claims that general exposure to all chemicals is broadly toxic in the absence of defined agents, doses, and pathways. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Chemical Toxicities”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Poor Digestion.
Poor Digestion
- Supports
- No high-quality evidence supports the claim as a specific medical assertion, because the claim is too vague to map to a diagnosable condition or intervention. None of the provided index papers address digestion, gastrointestinal symptoms, or treatment of poor digestion, so they do not support the claim .
- Contradicts
- The claim is not well-formed and cannot be validated against the provided evidence base. In evidence-based medicine, nonspecific terms like poor digestion require definition and clinical context before they can be evaluated; without that, there is no basis to treat it as established or proven. The provided index list is unrelated to digestion, which makes the evidence directly applicable to the claim essentially absent .
- Mainstream view
- Mainstream medical view is that poor digestion is a nonspecific symptom description, not a diagnosis, and it should be evaluated in context for causes such as dyspepsia, reflux, functional gastrointestinal disorders, food intolerance, medication effects, or organic disease. No meaningful conclusion about the influencer claim can be drawn from the supplied papers because they do not address the topic. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Poor Digestion”
Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to diagnose, treat, or cure Services.
Services
No specific health claims of theirs were cross-checked against the literature.
“Services”
Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Diagnosing and treating 'Metabolic Dysfunction' (systemic internal disease), which is outside the scope of a Chiropractor (DC) licensed only for musculoskeletal/nervous system care. as within their scope of practice.
Diagnosing and treating 'Metabolic Dysfunction' (systemic internal disease), which is outside the scope of a Chiropractor (DC) licensed only for musculoskeletal/nervous system care.
- Supports
- The influencer’s statement is too vague to be directly testable as a claim; however, it is consistent with the widely used concept that “metabolic dysfunction” refers to a cluster of cardiometabolic risk factors (obesity, insulin resistance, dysglycemia, dyslipidemia, hypertension) that underpin conditions such as type 2 diabetes, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). [9][12] High-quality consensus statements and guidelines explicitly define disease entities around the presence of metabolic dysfunction, for example metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where hepatic steatosis plus overweight/obesity, type 2 diabetes or other metabolic dysregulation are required criteria. [11] Systematic reviews and meta-analyses of pharmacologic and weight-loss interventions for MASLD/MASH consistently show that improving weight, insulin resistance and other metabolic parameters leads to histologic improvement of liver disease, supporting the central pathological role of metabolic dysfunction in these conditions. [10]
- Contradicts
- Because the influencer’s phrase is only “Metabolic Dysfunction” with no specific assertion (e. [10] g. , about its causes, prevalence, reversibility, or treatment), there is no concrete claim that can be contradicted or directly evaluated against trials or meta-analyses. Current expert commentary notes that there is no universally agreed, scientifically validated single definition of metabolic dysfunction itself; several proposed definitions (for example, using one or more cardiometabolic risk factors) have been described as somewhat arbitrary and lacking strong empirical justification. [11] This means that while the concept is widely used, precision about what exactly constitutes “metabolic dysfunction” varies across studies and guidelines, which weakens any claim that treats it as a singular, tightly defined disease entity. [12] Moreover, the trial and guideline literature around MASLD, metabolic hyperferritinaemia, or diabetes treatments focuses on specific diseases that occur in the context of metabolic dysfunction rather than on “metabolic dysfunction” as a standalone diagnosis, so evidence does not support treating it as a single condition with uniform treatment or prognosis. [9]
- Mainstream view
- In mainstream medicine, “metabolic dysfunction” is understood as a descriptive term for abnormalities in metabolic health—typically insulin resistance, visceral adiposity, dysglycemia, atherogenic dyslipidemia, and elevated blood pressure—that collectively increase risk for type 2 diabetes, cardiovascular disease and related organ damage. Leading expert groups have incorporated this concept into disease definitions, such as metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where the presence of hepatic steatosis plus clearly defined metabolic risk factors is required. [10][11][12] Consensus statements on entities like metabolic hyperferritinaemia likewise define them as occurring in individuals with metabolic dysfunction, and highlight their association with cardiometabolic and liver risk. [9] Mainstream guidance treats metabolic dysfunction not as a single formal diagnosis but as a modifiable risk-state underlying multiple conditions; recommended management focuses on lifestyle measures (diet, physical activity, weight loss, sleep hygiene), control of blood pressure, lipids and glycemia, and, when appropriate, pharmacologic agents (for example, GLP‑1 receptor agonists or other anti-obesity/antidiabetic drugs) that improve both metabolic parameters and downstream diseases such as MASLD/MASH. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Metabolic Dysfunction”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Diagnosing and treating 'Chemical Toxicities' (systemic toxicology), which is outside the scope of a Chiropractor and unsupported by chiropractic board rules. as within their scope of practice.
Diagnosing and treating 'Chemical Toxicities' (systemic toxicology), which is outside the scope of a Chiropractor and unsupported by chiropractic board rules.
- Supports
- The influencer claim is too vague to be matched directly to the listed index trials, which focus on specific interventions and diseases rather than general "chemical toxicities." For example, the lipid-lowering angiographic meta-analysis demonstrates that certain pharmacologic agents (statins and other lipid-lowering drugs) can beneficially modify coronary atherosclerosis, indicating that not all synthetic chemicals used in medicine are harmful and many have well-characterized benefit–risk profiles. The systematic review and meta-analysis of clinical dementia trials with EGb 761 (a standardized Ginkgo biloba extract) similarly evaluates efficacy and safety, suggesting that chemical exposures in therapeutic doses can be monitored and quantified for adverse effects, not simply assumed toxic. More broadly, high-quality toxicology and pharmacology evidence consistently shows that toxicity is dose-dependent and context-specific, and regulatory agencies require rigorous preclinical and clinical safety testing before approval of chemicals used in drugs, food additives, and consumer products.
- Contradicts
- Because the claim is undefined, any implication that all or most "chemicals" are inherently toxic or that everyday regulated exposures are broadly causing disease is not supported by the index papers provided or the wider evidence base. The lipid-lowering therapy meta-analysis shows net cardiovascular benefit with acceptable safety profiles at approved doses, contradicting alarmist narratives that such medications are generally harmful chemicals. The EGb 761 dementia trials review reports structured assessment of adverse events and safety, reinforcing that chemicals—whether plant-derived or synthetic—are evaluated for toxicity and used within margins of safety. Toxicology literature and regulatory science emphasize the principle that "the dose makes the poison" and that risk depends on exposure level, route, duration, and individual susceptibility, which contradicts blanket claims of ubiquitous chemical toxicity from ordinary, regulated exposures.
- Mainstream view
- The mainstream scientific and medical position is that toxicity is a quantitative, context-dependent property of substances, not a binary label applied to all "chemicals." Regulatory frameworks (e.g., for pharmaceuticals, pesticides, industrial chemicals, food additives) are built on toxicology principles, including dose–response relationships, no-observed-adverse-effect levels, and risk assessment that integrates hazard with exposure. Approved medications such as lipid-lowering agents and standardized herbal preparations like EGb 761 are used because their benefits outweigh their risks when dosed appropriately, while their potential toxicities are monitored through preclinical studies, clinical trials, and post-marketing surveillance. Mainstream medicine acknowledges real health risks from specific toxicants (e.g., lead, asbestos, high-dose solvents, certain air pollutants) and occupational or environmental exposures, but does not support undifferentiated claims that general exposure to all chemicals is broadly toxic in the absence of defined agents, doses, and pathways. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Chemical Toxicities”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Treatment of Metabolic Dysfunction as within their scope of practice.
Treatment of Metabolic Dysfunction
- Supports
- The influencer’s statement is too vague to be directly testable as a claim; however, it is consistent with the widely used concept that “metabolic dysfunction” refers to a cluster of cardiometabolic risk factors (obesity, insulin resistance, dysglycemia, dyslipidemia, hypertension) that underpin conditions such as type 2 diabetes, cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). [9][12] High-quality consensus statements and guidelines explicitly define disease entities around the presence of metabolic dysfunction, for example metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where hepatic steatosis plus overweight/obesity, type 2 diabetes or other metabolic dysregulation are required criteria. [11] Systematic reviews and meta-analyses of pharmacologic and weight-loss interventions for MASLD/MASH consistently show that improving weight, insulin resistance and other metabolic parameters leads to histologic improvement of liver disease, supporting the central pathological role of metabolic dysfunction in these conditions. [10]
- Contradicts
- Because the influencer’s phrase is only “Metabolic Dysfunction” with no specific assertion (e. [10] g. , about its causes, prevalence, reversibility, or treatment), there is no concrete claim that can be contradicted or directly evaluated against trials or meta-analyses. Current expert commentary notes that there is no universally agreed, scientifically validated single definition of metabolic dysfunction itself; several proposed definitions (for example, using one or more cardiometabolic risk factors) have been described as somewhat arbitrary and lacking strong empirical justification. [11] This means that while the concept is widely used, precision about what exactly constitutes “metabolic dysfunction” varies across studies and guidelines, which weakens any claim that treats it as a singular, tightly defined disease entity. [12] Moreover, the trial and guideline literature around MASLD, metabolic hyperferritinaemia, or diabetes treatments focuses on specific diseases that occur in the context of metabolic dysfunction rather than on “metabolic dysfunction” as a standalone diagnosis, so evidence does not support treating it as a single condition with uniform treatment or prognosis. [9]
- Mainstream view
- In mainstream medicine, “metabolic dysfunction” is understood as a descriptive term for abnormalities in metabolic health—typically insulin resistance, visceral adiposity, dysglycemia, atherogenic dyslipidemia, and elevated blood pressure—that collectively increase risk for type 2 diabetes, cardiovascular disease and related organ damage. Leading expert groups have incorporated this concept into disease definitions, such as metabolic dysfunction-associated fatty/steatotic liver disease (MAFLD/MASLD) in adults and children, where the presence of hepatic steatosis plus clearly defined metabolic risk factors is required. [10][11][12] Consensus statements on entities like metabolic hyperferritinaemia likewise define them as occurring in individuals with metabolic dysfunction, and highlight their association with cardiometabolic and liver risk. [9] Mainstream guidance treats metabolic dysfunction not as a single formal diagnosis but as a modifiable risk-state underlying multiple conditions; recommended management focuses on lifestyle measures (diet, physical activity, weight loss, sleep hygiene), control of blood pressure, lipids and glycemia, and, when appropriate, pharmacologic agents (for example, GLP‑1 receptor agonists or other anti-obesity/antidiabetic drugs) that improve both metabolic parameters and downstream diseases such as MASLD/MASH. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Metabolic Dysfunction”
Rule: Mo. Rev. Stat. §331.010(1)
Jaban Moore is not licensed or approved by Missouri State Board of Chiropractic Examiners to advertise Treatment of Chemical Toxicities as within their scope of practice.
Treatment of Chemical Toxicities
- Supports
- The influencer claim is too vague to be matched directly to the listed index trials, which focus on specific interventions and diseases rather than general "chemical toxicities." For example, the lipid-lowering angiographic meta-analysis demonstrates that certain pharmacologic agents (statins and other lipid-lowering drugs) can beneficially modify coronary atherosclerosis, indicating that not all synthetic chemicals used in medicine are harmful and many have well-characterized benefit–risk profiles. The systematic review and meta-analysis of clinical dementia trials with EGb 761 (a standardized Ginkgo biloba extract) similarly evaluates efficacy and safety, suggesting that chemical exposures in therapeutic doses can be monitored and quantified for adverse effects, not simply assumed toxic. More broadly, high-quality toxicology and pharmacology evidence consistently shows that toxicity is dose-dependent and context-specific, and regulatory agencies require rigorous preclinical and clinical safety testing before approval of chemicals used in drugs, food additives, and consumer products.
- Contradicts
- Because the claim is undefined, any implication that all or most "chemicals" are inherently toxic or that everyday regulated exposures are broadly causing disease is not supported by the index papers provided or the wider evidence base. The lipid-lowering therapy meta-analysis shows net cardiovascular benefit with acceptable safety profiles at approved doses, contradicting alarmist narratives that such medications are generally harmful chemicals. The EGb 761 dementia trials review reports structured assessment of adverse events and safety, reinforcing that chemicals—whether plant-derived or synthetic—are evaluated for toxicity and used within margins of safety. Toxicology literature and regulatory science emphasize the principle that "the dose makes the poison" and that risk depends on exposure level, route, duration, and individual susceptibility, which contradicts blanket claims of ubiquitous chemical toxicity from ordinary, regulated exposures.
- Mainstream view
- The mainstream scientific and medical position is that toxicity is a quantitative, context-dependent property of substances, not a binary label applied to all "chemicals." Regulatory frameworks (e.g., for pharmaceuticals, pesticides, industrial chemicals, food additives) are built on toxicology principles, including dose–response relationships, no-observed-adverse-effect levels, and risk assessment that integrates hazard with exposure. Approved medications such as lipid-lowering agents and standardized herbal preparations like EGb 761 are used because their benefits outweigh their risks when dosed appropriately, while their potential toxicities are monitored through preclinical studies, clinical trials, and post-marketing surveillance. Mainstream medicine acknowledges real health risks from specific toxicants (e.g., lead, asbestos, high-dose solvents, certain air pollutants) and occupational or environmental exposures, but does not support undifferentiated claims that general exposure to all chemicals is broadly toxic in the absence of defined agents, doses, and pathways. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Chemical Toxicities”
Rule: Mo. Rev. Stat. §331.010(1)
Manipulation
False Authority
transcript · cited
The subject uses a Chiropractor (DC) license to claim they can diagnose and treat systemic diseases like 'Metabolic Dysfunction' and 'Chemical Toxicities', which is outside their legal scope and creates a false impression of medical authority. Likely motive: To attract patients with chronic systemic illnesses who are looking for a 'root cause' solution, bypassing the limitations of standard chiropractic care.
“Addressing the underlying causes of disease by addressing the whole person”
Cherry-Picked Evidence
transcript · cited
The subject cites a single anecdote where a mother was diagnosed with diabetes only after a car accident to imply that mainstream medicine is incompetent at finding 'root causes', ignoring the fact that diabetes is often asymptomatic until complications arise. Likely motive: To undermine trust in standard medical diagnosis and position the chiropractor as the only one who can find the 'true' cause.
“She was diagnosed only because she was in a car accident and in the ER she was told that she was diabetic.”
Fear Mongering
transcript · cited
The subject uses absolute language ('not a question of IF') to claim everyone has toxic overload, creating fear to sell the 'Ionic Foot Bath' detox service. Likely motive: To generate anxiety about 'toxins' and sell the proprietary detox foot bath as a necessary solution.
“Researchers and experts in environmental medicine tell us that it is not a question of IF our bodies are burdened with toxic overload, but more 'how bad is it.'”
False Dichotomy
transcript · cited
The subject frames care as a binary choice: either their 'whole person' approach or the 'isolated' (and implied inferior) standard medical approach, ignoring that standard medicine also treats patients holistically. Likely motive: To position their alternative care as superior by falsely demonizing standard medical practices.
“not just and isolated set of symptoms”
Commerce & grift map
The subject uses fear of 'toxic overload' to sell a proprietary 'MaX Detox Foot Bath' service, while simultaneously claiming to treat systemic diseases (Metabolic Dysfunction, Chemical Toxicities) outside their chiropractic scope. This creates a funnel where patients with chronic systemic issues are drawn in by the 'root cause' promise and monetized through the in-office detox service.
No FTC-style compensation disclosure
compensationDisclosures · scan
The subject promotes the 'MaX Detox Foot Bath System' as a proprietary detox service.
proprietary_product
Host self-funnel around guest content
guestCollaboration · selfFunnel
Host routes viewers to their own consult/booking links around the guest segment.
How the money flows
- Proprietary productUndisclosed The subject promotes the 'MaX Detox Foot Bath System' as a proprietary detox service. “The MaX Detox Foot Bath System is one of the safest detoxification processes”
“The MaX Detox Foot Bath System is one of the safest detoxification processes”
Sponsors and advertisers
Brands, advertisers, and agencies connected to this content, based on what it promotes and discloses.
- MaX DetoxBrand
Promoted commerce partner
Credentials & scope
Glossary: Chiropractor (“Dr.”)
Stated: Chiropractor
Verified against the federal provider registry: D.C. · Chiropractor · MO license 2013013283.
The subject holds a Chiropractor license but advertises diagnosing and treating systemic diseases (Metabolic Dysfunction, Chemical Toxicities, Leaky Gut), which is a clear case of credential inflation.
- D.C., Doctor of Chiropractic
A professional degree for chiropractors, licensed to treat musculoskeletal and nervous system conditions via spinal adjustment.
State chiropractic boards limit scope to musculoskeletal/nervous system; do not allow diagnosis or treatment of systemic diseases like diabetes, metabolic dysfunction, or chemical toxicities.
Permitted scope vs advertised
Missouri State Board of Chiropractic Examiners · Confidence: high
Missouri defines the practice of chiropractic as examination, diagnosis, adjustment, manipulation, and treatment by methods commonly taught in accredited chiropractic colleges, and expressly states that chiropractic is not the practice of medicine and does not include prescribing drugs, operative surgery, obstetrics, osteopathy, podiatry, or the practice of medicine.[1] The statute allows additional use of meridian therapy/acupressure/acupuncture with appropriate board certification.[1] Chiropractors therefore have authority to diagnose and treat conditions using chiropractic methods, but not to practice general internal medicine or systemic medical specialties.
What this license permits
- Spinal adjustment and manipulation
- Musculoskeletal evaluation and treatment
- Soft-tissue and rehabilitative care
- Headache care within musculoskeletal scope
15 of 15 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| Listed service Leaky Gut Rule: Mo. Rev. Stat. §331.010(1) Missouri law authorizes chiropractic diagnosis and treatment only by methods commonly taught in accredited chiropractic programs and excludes the practice of medicine, and "leaky gut" is a speculative systemic/internal diagnosis not recognized as a standard chiropractic diagnosis under that statutory definition. | Outside scope |
| She was diagnosed only because she was in a car accident and in the ER she was told that she was diabetic. Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) | Outside scope |
| Diagnosing and treating 'Leaky Gut' (digestive/systemic disease), which is outside the scope of a Chiropractor and not a recognized condition for chiropractic treatment. Rule: Mo. Rev. Stat. §331.010(1) Diagnosing and treating a systemic gastrointestinal/internal disease such as "leaky gut" constitutes practice of medicine rather than chiropractic, which Missouri statute explicitly excludes from the chiropractic scope. | Outside scope |
| Treatment of Leaky Gut Rule: Mo. Rev. Stat. §331.010(1) Treating "leaky gut" as a systemic gastrointestinal disease is a form of internal medical care, whereas Missouri only authorizes treatment by chiropractic methods and declares chiropractic is not the practice of medicine. | Outside scope |
| Listed service Metabolic Dysfunction Rule: Mo. Rev. Stat. §331.010(1) Labeling or managing broad "metabolic dysfunction" implies diagnosis of systemic endocrine/metabolic disease, which falls within the practice of medicine rather than chiropractic as narrowly defined in Missouri. | Outside scope |
| Listed service Chemical Toxicities Rule: Mo. Rev. Stat. §331.010(1) Diagnosing "chemical toxicities" constitutes systemic toxicology/medical evaluation, which is not affirmatively authorized and is excluded as the practice of medicine under Missouri’s chiropractic statute. | Outside scope |
| Listed service Poor Digestion Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Services Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Diagnosing and treating 'Metabolic Dysfunction' (systemic internal disease), which is outside the scope of a Chiropractor (DC) licensed only for musculoskeletal/nervous system care. Rule: Mo. Rev. Stat. §331.010(1) Systemic metabolic and internal diseases are part of the practice of medicine, and Missouri’s chiropractic definition authorizes only chiropractic methods and explicitly states chiropractic is not the practice of medicine. | Outside scope |
| Diagnosing and treating 'Chemical Toxicities' (systemic toxicology), which is outside the scope of a Chiropractor and unsupported by chiropractic board rules. Rule: Mo. Rev. Stat. §331.010(1) Systemic toxicology evaluation and management are medical functions, while Missouri law does not affirmatively authorize chiropractors to practice toxicology and instead excludes the practice of medicine from chiropractic. | Outside scope |
| Claiming to address 'underlying causes of disease' (systemic/internal medicine) as a Chiropractor, which is outside the scope of practice for a DC license. Rule: Mo. Rev. Stat. §331.010(1) Advertising that one addresses the underlying causes of general disease implies a broad internal-medicine role, whereas Missouri defines chiropractic as distinct from and not including the practice of medicine. | Outside scope |
| Treatment of Metabolic Dysfunction Rule: Mo. Rev. Stat. §331.010(1) Treating "metabolic dysfunction" in a systemic sense is medical/endocrine care, which is not affirmatively permitted and is excluded as the practice of medicine under the Missouri chiropractic statute. | Outside scope |
| Treatment of Chemical Toxicities Rule: Mo. Rev. Stat. §331.010(1) Managing or detoxifying "chemical toxicities" is systemic toxicology treatment, which falls within medical practice and is not authorized for chiropractors under §331.010. | Outside scope |
| MaX Detox Foot Bath System Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) A "detox" foot bath marketed to remove systemic toxins | Outside scope |
| Neuro Emotional Technique (NET) for chronic physical problems Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
Sources: Missouri Revised Statutes §331.010 – Practice of chiropractic, definition (official), Missouri State Board of Chiropractic Examiners – Statutes page (official), Practice of chiropractic, definition. :: 2025 Missouri Revised ..., Revised Statutes of Missouri, RSMo Section 334.506 - MO.gov (official)
Scope comparison mirror
Side-by-side view of the archived marketing homepage and what a Chiropractor scope permits near NORTH KANSAS CITY, MO. Open the mirror for the full comparison: archive on the left, permitted scope and licensed-care paths on the right.
Mirror generated 2026-07-16 19:31 UTC. The archive pane loads styles and images from the intake snapshot.
3 licensed-care paths linked for out-of-scope claims.
Validated associated properties
Surfaces tied to this Doc Bro by domain, branding, or funnel routing. Third-party platforms are labeled as routes, not as owned properties.
Analyzed
- OwnedOfficial site (drjabanmoore.com)
- Operated funnelPractice site (redefiningwellnesscenter.com)
- Linked entityLinked commerce or practice (m.drjaban.com)
Funnel routes (third-party)
- Hosted routeFunnel route on amazon.com
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission 5YedKPFGrU_6E8Y6LOsEe
Fight disinformation
Log a public thread where Jaban Moore is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked Jaban Moore's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/5YedKPFGrU_6E8Y6LOsEe. White-coat charisma isn't evidence.
Full DTMB scan on Jaban Moore: https://drtrustmebro.com/analyze/5YedKPFGrU_6E8Y6LOsEe
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
- Other
Catching the Red Flags, with Michael Rubino
Interview page that features his mold and toxin claims.
- YouTube
Stop Masking Symptoms and Get to the Root Cause of Your Illness
Interview appearance with an open comment thread.
- Other
Episode 52: The Dangers of Chemical Toxicities with Jaban Moore
Podcast interview page where the pitch reaches a new audience.
- YouTube
Nervous System Dysregulation: The Invisible Barrier to Recovery
One of Jaban M Moore's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
- YouTube
How Dr. Jill Carnahan Uses Peptides for Mold, MCAS, and Chronic Illness
One of Jaban M Moore's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
Nudge the Doc Bro
We email a public contact address from their site so Jaban Moore can review this dossier and dispute anything we got wrong.
Know someone who can help?
If you think someone has firsthand information about Jaban Moore, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for Jaban Moore. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: LHGCVS_CZpjf-As5HKrmZ
- Wall entry: /influencer/LHGCVS_CZpjf-As5HKrmZ
- Analysis ID: 5YedKPFGrU_6E8Y6LOsEe
- Source: https://www.redefiningwellnesscenter.com/
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Guideline-Driven Management of Hypertension: An Evidence-Based Update.
- [2] ASPEN-FELANPE Clinical Guidelines.
- [3] ESPEN guideline: Clinical nutrition in inflammatory bowel disease.
- [4] When Is Parenteral Nutrition Appropriate?
- [5] Intestinal permeability – a new target for disease prevention and therapy
- [6] Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise
- [7] The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation
- [8] Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review
- [9] Consensus Statement on the definition and classification of metabolic hyperferritinaemia
- [10] The Impact of Body Weight Change on Liver Histology in Metabolic ...
- [11] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial - Nature Medicine
- [12] Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis